Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 419-423

  Naderer, Odin J ^a   Rodvold, Keith A ^b   Jones, Lori S ^a   Zhu, John Z ^a   Bowen, Chester L ^a   Chen, Liangfu ^a   Dumont, Etienne ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DIPHENHYDRAMINE; GSK 1322322; GSK1322322; METHYLPREDNISOLONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; INFUSION SITE PAIN; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITIC RASH; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; BRONCHOALVEOLAR LAVAGE; FEMALE; HUMANS; HYDROXAMIC ACIDS; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 84891546982     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01836-13     Document Type: Article

References (16)

1. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N. Engl. J. Med. 368:299-302. http://dx.doi.org/10.1056/ NEJMp1215093.
2. Livermore DM. 2011. Discovery research: The scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66:1941-1944. http://dx.doi.org/10.1093/jac/dkr262.
3. Apfel CM, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W, Page MGP, Keck W. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45:1058-1064. http://dx.doi.org/10.1128/AAC.45.4.1058-1064.2001.
4. Jain R, Chan D, White RJ, Patel DV, Yuan Z. 2005. Bacterial peptide deformylase inhibitors: A new class of antibacterial agents. Curr. Med. Chem. 12:1607-1621. http://dx.doi.org/10.2174/0929867054367194.
5. Sutcliffe JA. 2011. Antibiotics in development targeting protein synthesis. Ann. N. Y. Acad. Sci. 1241:122-152. http://dx.doi.org/10.1111/j.1749- 6632.2011.06323.x.
6. Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN. 2011. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J. Clin. Microbiol. 49:3928-3930. http://dx.doi.org/10.1128/JCM.01213-11.
7. O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D. 2013. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob. Agents Chemother. 57:2333-2342. http://dx.doi.org/10.1128/AAC.02566-12.
8. 2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. Antimicrob. Agents Chemother. 57:2556-2561. http://dx.doi.org/10.1128/AAC.02505-12.
9. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 57: 2005-2009. http://dx.doi.org/10.1128/AAC.01779-12.
10. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Safety, tolerability, and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: A randomized placebocontrolled study. J. Antimicrob. Chemother. 68:1901-1909. http://dx.doi.org/10.1093/JAC/ dkt097.
11. Rodvold KA, George JM, Yoo L. 2011. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin. Pharmacokinet. 50:637-664. http://dx.doi.org/10.2165/11594090-000000000-00000.
12. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic- pharmacodynamic considerations in the design of hospitalacquired or ventilator-acquired bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51(Suppl 1):S103-S110. http://dx.doi.org/10.1086/ 653057.
13. Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, Rodvold KA. 2011. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob. Agents Chemother. 55:5178-5184. http://dx.doi.org/ 10.1128/AAC.00703-11.
14. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538.
15. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. 1990. Azithromycin concentrations at the sites of pulmonary infections. Eur. Respir. J. 3:886-890.
16. Naderer OJ, Jones LS, Zhu J, Kurtinecz M, Dumont E. 2013. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. J. Clin. Pharmacol. 53: 1168-1176. http://dx.doi.org/10.1002/jcph.150.